BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Laurus Labs Ltd. Share Price

NSE
BSE

NSE : LAURUSLABS

BSE : 540222

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹1,365.10

High

₹1,391.50

Price Summary

Previous Close ₹1,381.70
Day's Range ₹1,365.10 - ₹1,391.50
Open ₹1,369.90
52 Week Range ₹604.00 - ₹1,391.50
Volume 13,11,180
Market Cap ₹0.07

Stocks Summary

Trade Value ( ₹ in Lacs) 18,133.90
Market Cap (₹ in Mn) 0.07
Dividend Yield(%) 0.14
Price/Earning (TTM) 83.89
TTM EPS (₹) 16.46
P/E Ratio 92.37
Book Value(₹) 14.07
PAT Margin (%) 6.38
Face Value (₹) 2.00
ROCE(%) 10.16

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 52169.8 16500.1
Expenses N/A N/A
PBT 5038.1 3302.0
Operating profit 0.0 0.0
Net profit 3803.9 2519.0

Shareholding Pattern

Promoters (% Holding)

27.49%

Mutual funds (% Holding)

11.22%

Non-Institution (% Holding)

32.71%

FI/Banks/Insurance (% Holding)

1.50%

Government (% Holding)

0.00%

FII

25.82%

About Laurus Labs Ltd.

Founded 2005
NSE Symbol LAURUSLABS

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,42,677.30 1,843.45 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,80,457.58 6,805.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,53,684.69 4,539.50 3,102.00 - 3,102.00
Apollo Hospitals Enterprise Ltd. 1,18,999.06 8,276.20 6,696.50 - 6,696.50
Cipla Ltd. 1,14,562.27 1,419.45 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,10,095.43 1,320.50 1,148.40 - 1,148.40
Zydus Lifesciences Ltd. 1,09,271.98 1,085.95 835.50 - 835.50
Lupin Ltd. 1,04,096.62 2,273.75 1,836.80 - 1,836.80
Mankind Pharma Ltd. 99,957.06 2,436.90 1,909.70 - 1,909.70
Max Healthcare Institute Ltd. 96,852.36 995.50 903.00 - 903.00
no-content No Records Found

Latest News

May
8
2026
EQUITY Posted on May 8th 2026

Laurus Labs informs about newspaper advertisements

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed copies of the newspaper advertisements pertaining to Notice to Shareholders with respect to, ‘Submission of TDS related documents for 2nd Interim Dividend for FY 2025-26’. The advertisements were published in ‘Business Standard’ (English) and ‘Prajasakti’ (Telugu) on May 07, 2026.

The above information is a part of company’s filings submitted to BSE.
Read More
May
2
2026
EQUITY Posted on May 2nd 2026

Laurus Labs informs about press release

Laurus Labs has informed that it enclosed copies of the newspaper advertisement pertaining to Financial Results of the Company for the quarter and year ended March 31, 2026. The advertisements were published in Business Standard (English) and Prajasakti (Telugu) on May 01, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
May
28
2026
COMPANY Posted on May 28th 2026

FDC - Quaterly Results

The revenue zoomed 17.09% to Rs. 5643.64 millions for the quarter ended March 2026 as compared to Rs. 4820.04 millions during the corresponding quarter last year.Net Profit witnessed a 122.07% growth almost the double from Rs. 482.15 millions to Rs. 1070.70  millions  of same quarter last year.The company reported a good operating profit of 1587.76 millions compared to 842.52 millions of corresponding previous quarter.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 5643.64 4820.04 17.09 21263.27 20701.12 2.72 21263.27 20701.12 2.72
Other Income 471.64 314.26 50.08 1110.01 1055.18 5.20 1110.01 1055.18 5.20
PBIDT 1587.76 842.52 88.45 4631.81 4257.65 8.79 4631.81 4257.65 8.79
Interest 14.99 11.82 26.82 49.24 44.88 9.71 49.24 44.88 9.71
PBDT 1572.77 830.70 89.33 4374.68 4212.77 3.84 4374.68 4212.77 3.84
Depreciation 143.13 155.29 -7.83 591.04 536.06 10.26 591.04 536.06 10.26
PBT 1429.64 675.41 111.67 3783.64 3676.71 2.91 3783.64 3676.71 2.91
TAX 358.94 193.26 85.73 924.40 940.46 -1.71 924.40 940.46 -1.71
Deferred Tax 48.94 37.36 31.00 61.40 90.46 -32.12 61.40 90.46 -32.12
PAT 1070.70 482.15 122.07 2859.24 2736.25 4.49 2859.24 2736.25 4.49
Equity 162.81 162.81 0.00 162.81 162.81 0.00 162.81 162.81 0.00
PBIDTM(%) 28.13 17.48 60.95 21.78 20.57 5.91 21.78 20.57 5.91
Read More
May
28
2026
COMPANY Posted on May 28th 2026

Hikal - Quaterly Results

A decrease in the sales to Rs. 5194.00 millions was observed for the quarter ended March 2026. The sales stood at Rs. 5524.00 millions during the similar quarter previous year.Net Profit of the company move down -70.97% to Rs. 146.00  millions from Rs. 503.00 millions  in the same quarter last year.The company reported a degrowth in operating Profit to 1122.00 millions from 1240.00 millions.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 5194.00 5524.00 -5.97 17126.00 18598.00 -7.91 17126.00 18598.00 -7.91
Other Income 66.00 5.00 1220.00 123.00 50.00 146.00 123.00 50.00 146.00
PBIDT 1122.00 1240.00 -9.52 2328.00 3335.00 -30.19 2328.00 3335.00 -30.19
Interest 146.00 179.00 -18.44 621.00 752.00 -17.42 621.00 752.00 -17.42
PBDT 505.00 1061.00 -52.40 856.00 2583.00 -66.86 856.00 2583.00 -66.86
Depreciation 420.00 377.00 11.41 1638.00 1344.00 21.88 1638.00 1344.00 21.88
PBT 85.00 684.00 -87.57 -782.00 1239.00 -163.12 -782.00 1239.00 -163.12
TAX -61.00 181.00 -133.70 -295.00 330.00 -189.39 -295.00 330.00 -189.39
Deferred Tax -41.00 8.00 -612.50 -275.00 30.00 -1016.67 -275.00 30.00 -1016.67
PAT 146.00 503.00 -70.97 -487.00 909.00 -153.58 -487.00 909.00 -153.58
Equity 247.00 247.00 0.00 247.00 247.00 0.00 247.00 247.00 0.00
PBIDTM(%) 21.60 22.45 -3.77 13.59 17.93 -24.19 13.59 17.93 -24.19
Read More
May
28
2026
COMPANY Posted on May 28th 2026

Godavari Drugs - Quaterly Results

The sales moved up 30.04% to Rs. 331.63 millions for the March 2026 quarter as compared to Rs. 255.03 millions during the year-ago period.A comparatively good net profit growth of 44.34% to Rs. 12.89 millions was reported for the quarter ended March 2026 compared to Rs. 8.93 millions of previous same quarter.The company reported a degrowth in operating Profit to 30.80 millions from 32.19 millions.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 331.63 255.03 30.04 1058.08 1133.50 -6.65 1058.08 1133.50 -6.65
Other Income 1.41 1.05 34.29 8.05 9.77 -17.60 8.05 9.77 -17.60
PBIDT 30.80 32.19 -4.32 111.19 128.04 -13.16 111.19 128.04 -13.16
Interest 9.56 11.07 -13.64 39.80 47.32 -15.89 39.80 47.32 -15.89
PBDT 22.28 21.12 5.49 74.94 80.72 -7.16 74.94 80.72 -7.16
Depreciation 6.12 6.72 -8.93 24.32 24.48 -0.65 24.32 24.48 -0.65
PBT 16.16 14.40 12.22 50.62 56.24 -9.99 50.62 56.24 -9.99
TAX 3.27 5.47 -40.22 9.74 12.45 -21.77 9.74 12.45 -21.77
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 12.89 8.93 44.34 40.88 43.79 -6.65 40.88 43.79 -6.65
Equity 101.27 75.30 34.49 101.27 75.30 34.49 101.27 75.30 34.49
PBIDTM(%) 9.29 12.62 -26.42 10.51 11.30 -6.97 10.51 11.30 -6.97
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Laurus Labs Ltd. ?

The current share price of Laurus Labs Ltd. is ₹1,381.70 as of 2026-05-27.

The market capitalisation of Laurus Labs Ltd. is ₹74,562.29 as of 2026-05-27.

The 1-year return of Laurus Labs Ltd. is 0.00% as of 2026-05-27.

The P/E ratio of Laurus Labs Ltd. is 92.37 as of 2026-05-28.

The 52-week high and low of Laurus Labs Ltd. are ₹1,391.50 and ₹604.00, respectively, as of 2026-05-27.

The dividend yield of Laurus Labs Ltd. is 0.1448% as of2026-05-27.

You can buy Laurus Labs Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Laurus Labs Ltd. is .

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

People Also Ask

What healthcare products are provided by Laurus Labs Ltd.?

Laurus Labs Ltd. provides active pharmaceutical ingredients, generic formulations and contract‑development/manufacturing services, with strengths in antivirals, oncology and chronic therapies.

Laurus Labs Ltd. collaborates via API and formulation supply agreements and CDMO partnerships with global generic and branded pharma companies that serve hospitals worldwide.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore